Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

US6919342B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Andreas Haupt · Ludwigshafen, DE
• Roland Grandel · Dossenheim, DE
• Wilfried Braje · Ludwigshafen, DE
• Hervé Geneste · Schifferstadt, DE
• Karla Drescher · Ludwigshafen, DE
• Dorothea Starck · Ludwigshafen, DE
• Hans-Jurgen Teschendorf · Dudenhofen, DE

Key dates

• Filing date: Jun 4, 2004
• Grant date: Jul 19, 2005
• Expiry date: Jun 4, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to triazole compounds of the general formula I wherein The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.